Nifurtimox

Edina Avdic, Pharm.D., Paul A. Pham, Pharm.D.
Nifurtimox is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Not commercially available in the U.S.
    • Available from the CDC under investigational protocols. Drug can be obtained by callingParasitic Diseases Public Inquiries (404-718-4745; e-mail chagas@cdc.gov). Outside of regular business hours call the CDC Emergency Operations Center (770-488-7100) and ask for the person on call for parasitic diseases.

NON-FDA APPROVED USES

  • American trypanosomiasis (Chagas’ disease, T. cruzi): acute early phase of the disease.
  • May be used in combination with eflornithine for the treatment of second-stage sleeping sickness.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Not commercially available in the U.S.
    • Available from the CDC under investigational protocols. Drug can be obtained by callingParasitic Diseases Public Inquiries (404-718-4745; e-mail chagas@cdc.gov). Outside of regular business hours call the CDC Emergency Operations Center (770-488-7100) and ask for the person on call for parasitic diseases.

NON-FDA APPROVED USES

  • American trypanosomiasis (Chagas’ disease, T. cruzi): acute early phase of the disease.
  • May be used in combination with eflornithine for the treatment of second-stage sleeping sickness.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: June 7, 2017